2019年6月科睿唯安发布的期刊引证报告中，SAGE期刊呈现了良好的增长趋势。今天，我们来看看这本SCI期刊：Therapeutic Advances in Musculoskeletal Disease (TAMD)。
风湿病学
Therapeutic Advances in Musculoskeletal Disease (TAMD)是经过同行评审的开放获取期刊，发表骨质疏松症和风湿病药物治疗领域的前沿探索和创新研究。期刊侧重于临床和药理学领域，主要受众群体为全球风湿病学、骨质疏松症和相关学科临床医生和研究人员。该刊最新影响因子(JCR2018)为5.045，相较JCR2017增长了46%。
The journal has an Impact Factor of 5.045 and is ranked 6 out 31 Journals in the Rheumatology category.
We encourage submissions and welcome articles on all aspects of the diagnosis, prevention and management of rheumatic diseases, osteoporosis and other musculoskeletal diseases. We offer a number of different resources to maximise the visibility of your research and reach a broad audience.
Authors will enjoy:
Launched in 2009
Impact Factor: 5.045
Ranked 6 out of 31 in Rheumatology
Listed in PubMed and freely available via PubMed Central and the journal website, leading to broader readership
Rigorous peer review
Rapid publication
Over 500,000 article views on PubMed Central in 2018
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
